Enanta Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 10.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 311.93M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...